{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:35:08Z","timestamp":1783488908439,"version":"3.55.0"},"reference-count":116,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Retinal vascular diseases, such as diabetic retinopathy or retinal vein occlusion, are common causes of severe vision loss. Central to the pathophysiology of these conditions are endothelial dysfunction, inflammation, capillary leakage, ischemia, and pathological neoangiogenesis. Capillary damage leads to leakage and the development of macular edema, which is associated with vision loss and requires complex treatment. Sulodexide, a glycosaminoglycan composed of heparan sulfate and dermatan sulfate with high oral bioavailability, exhibits several favorable pharmacologic properties, including antithrombotic, anti-inflammatory, and endothelium-protective effects. Additionally, treatment with sulodexide has been associated with the reduction of oxidative stress and decreased expression of angiogenic growth factors, such as vascular endothelial growth factor. This review aims to provide an overview of the pharmacological properties, mechanisms of action, and therapeutic effects of sulodexide. Furthermore, its potential for clinical application in venous and diabetic diseases, such as venous thromboembolism, chronic venous insufficiency, peripheral artery disease, or diabetic nephropathy, is summarized. We also present experimental and clinical studies evaluating the potential of sulodexide in ocular conditions and discuss its therapeutic implications for the treatment of retinal vascular diseases.<\/jats:p>","DOI":"10.1055\/s-0044-1791232","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T23:01:04Z","timestamp":1726700464000},"page":"291-307","source":"Crossref","is-referenced-by-count":9,"title":["Potential of Sulodexide in the Treatment of Diabetic Retinopathy and Retinal Vein Occlusion"],"prefix":"10.1055","volume":"125","author":[{"given":"Elsa Wilma","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Buonfiglio","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Korb","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Dauth","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Br\u0119borowicz","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland"},{"name":"Collegium Medicum, Zielona G\u00f3ra University, Zielona G\u00f3ra, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gericke","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"102967","DOI":"10.1016\/j.redox.2023.102967","article-title":"Oxidative stress in the eye and its role in the pathophysiology of ocular diseases","volume":"68","author":"E W B\u00f6hm","year":"2023","journal-title":"Redox Biol"},{"issue":"15","key":"ref2","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurjpc\/zwad075","article-title":"Mitigation of aircraft noise-induced vascular dysfunction and oxidative stress by exercise, fasting, and pharmacological \u03b11AMPK activation: molecular proof of a protective key role of endothelial \u03b11AMPK against environmental noise exposure","volume":"30","author":"M Kvandov\u00e1","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal vascular occlusions","volume":"396","author":"I U Scott","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"ref4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between","volume":"122","author":"C Chattopadhyay","year":"2016","journal-title":"Cancer"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.14324","article-title":"Sulodexide in venous disease","volume":"17","author":"B J Carroll","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s12325-021-01620-1","article-title":"Sulodexide for diabetic-induced disabilities: a systematic review and meta-analysis","volume":"38","author":"A A Bignamini","year":"2021","journal-title":"Adv Ther"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1742-4658.2012.08529.x","article-title":"Glycosaminoglycans: key players in cancer cell biology and treatment","volume":"279","author":"N Afratis","year":"2012","journal-title":"FEBS J"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jpba.2018.04.012","article-title":"Fine structural characterization of sulodexide","volume":"156","author":"N Veraldi","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/DDDT.S6762","article-title":"Development and use of sulodexide in vascular diseases: implications for treatment","volume":"8","author":"S Coccheri","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"e48632","DOI":"10.1371\/journal.pone.0048632","article-title":"On the specificity of heparin\/heparan sulfate binding to proteins. Anion-binding sites on antithrombin and thrombin are fundamentally different","volume":"7","author":"P D Mosier","year":"2012","journal-title":"PLoS One"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4","article-title":"Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide","volume":"18","author":"J Harenberg","year":"1998","journal-title":"Med Res Rev"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"117R","DOI":"10.1093\/glycob\/cwf066","article-title":"Dermatan sulfate: new functions from an old glycosaminoglycan","volume":"12","author":"J M Trowbridge","year":"2002","journal-title":"Glycobiology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1877-1173(10)93015-9","article-title":"Vascular dermatan sulfate and heparin cofactor II","volume":"93","author":"D M Tollefsen","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref14","first-page":"161","article-title":"Pharmacokinetics of sulodexide evaluated from 131I-labelled fast-moving heparin after single intravenous and oral administration on man at different doses","volume":"3","author":"M Milani","year":"1992","journal-title":"Br J Clin Res"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-2007-1001916","article-title":"Organ glycosaminoglycan distribution after intravenous and oral administration in rats","volume":"20","author":"E Marchi","year":"1994","journal-title":"Semin Thromb Hemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0049-3848(03)00246-9","article-title":"Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans","volume":"109","author":"B Cosmi","year":"2003","journal-title":"Thromb Res"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1076029609338048","article-title":"Full-length TFPI release by heparinoid sulodexide","volume":"16","author":"J Borawski","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1076029609338711","article-title":"Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide","volume":"15","author":"C Adiguzel","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/FTD.0000000000000157","article-title":"Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method","volume":"37","author":"S Du","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1185\/03007999309111537","article-title":"Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation","volume":"13","author":"M Mauro","year":"1993","journal-title":"Curr Med Res Opin"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02591420","article-title":"Antithrombotic and thrombolytic activity of sulodexide in rats","volume":"22","author":"M Barbanti","year":"1992","journal-title":"Int J Clin Lab Res"},{"issue":"02","key":"ref22","first-page":"225","article-title":"Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide","volume":"19","author":"A Ceriello","year":"1993","journal-title":"Diabete Metab"},{"issue":"05","key":"ref23","first-page":"189","article-title":"Sulodexide oral administration influences blood viscosity and fibrinolysis","volume":"18","author":"G Crepaldi","year":"1992","journal-title":"Drugs Exp Clin Res"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00044011-199510030-00005","article-title":"Pharmacodynamic effects of sulodexide on profibrinolytic and haemorrheological patterns","volume":"10","author":"G L Messa","year":"1995","journal-title":"Clin Drug Investig"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-2007-1001909","article-title":"Interaction between glycosaminoglycans, platelets, and leukocytes","volume":"20","author":"C Cerletti","year":"1994","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1002\/cphy.c210029","article-title":"Endothelial glycocalyx","volume":"12","author":"C A Foote","year":"2022","journal-title":"Compr Physiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1479-5876-10-213","article-title":"A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition","volume":"10","author":"V Masola","year":"2012","journal-title":"J Transl Med"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/ATVBAHA.112.254961","article-title":"Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression","volume":"33","author":"M Blich","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"53","key":"ref29","doi-asserted-by":"crossref","first-page":"91350","DOI":"10.18632\/oncotarget.20518","article-title":"Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model","volume":"8","author":"T Li","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1007\/s00125-010-1910-x","article-title":"Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus","volume":"53","author":"L N Broekhuizen","year":"2010","journal-title":"Diabetologia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1172892","DOI":"10.3389\/fimmu.2023.1172892","article-title":"Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis","volume":"14","author":"J Ying","year":"2023","journal-title":"Front Immunol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1570161111311030010","article-title":"Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases","volume":"11","author":"F Mannello","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FJC.0000000000000778","article-title":"Sulodexide improves contraction and decreases matrix metalloproteinase-2 and -9 in veins under prolonged stretch","volume":"75","author":"J D Raffetto","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/DDDT.S61770","article-title":"The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs","volume":"8","author":"R Serra","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1570161111666131126144025","article-title":"Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease","volume":"12","author":"F Mannello","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.bbadis.2016.07.018","article-title":"Chronic venous disease - Part I: inflammatory biomarkers in wound healing","volume":"1862","author":"D Ligi","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"02","key":"ref37","first-page":"140","article-title":"Sulodexide reduces the inflammatory reaction and senescence of endothelial cells in conditions involving chronic venous disease","volume":"35","author":"T Urbanek","year":"2016","journal-title":"Int Angiol"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.trsl.2008.12.007","article-title":"Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity","volume":"153","author":"M Ciszewicz","year":"2009","journal-title":"Transl Res"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.3390\/ijms18102206","article-title":"Chronic venous insufficiency: transforming growth factor-\u03b2 isoforms and soluble endoglin concentration in different states of wound healing","volume":"18","author":"D Ligi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"02","key":"ref40","first-page":"103","article-title":"The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus","volume":"99","author":"J Skrha","year":"1998","journal-title":"Sb Lek"},{"key":"ref41","first-page":"4989847","article-title":"Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating Klotho expression at an early stage of diabetic kidney disease","volume":"2017","author":"Y N Liu","year":"2017","journal-title":"J Diabetes Res"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1111\/jcmm.14367","article-title":"Sulodexide attenuates endoplasmic reticulum stress induced by myocardial ischaemia\/reperfusion by activating the PI3K\/Akt pathway","volume":"23","author":"D Shen","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"17","key":"ref43","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.3390\/molecules27175465","article-title":"Sulodexide increases glutathione synthesis and causes pro-reducing shift in glutathione-redox state in HUVECs exposed to oxygen-glucose deprivation: implication for protection of endothelium against ischemic injury","volume":"27","author":"K Bontor","year":"2022","journal-title":"Molecules"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mvr.2015.10.001","article-title":"Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation","volume":"103","author":"B Gabryel","year":"2016","journal-title":"Microvasc Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bcp.2019.04.021","article-title":"Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway","volume":"166","author":"J D Raffetto","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.33549\/physiolres.931506","article-title":"Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats","volume":"57","author":"V Kristov\u00e1","year":"2008","journal-title":"Physiol Res"},{"issue":"04","key":"ref47","first-page":"467","article-title":"Effect of sulodexide on aortic vasodilation capacity and associated morphological changes in rats with streptozotocin-induced diabetes [in Spanish]","volume":"51","author":"J V\u00e1squez","year":"2010","journal-title":"Invest Clin"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0021-9150(90)90071-P","article-title":"Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use","volume":"81","author":"G Crepaldi","year":"1990","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0049-3848(86)90276-8","article-title":"The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects","volume":"41","author":"L Pisano","year":"1986","journal-title":"Thromb Res"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1016\/j.bbadis.2018.09.022","article-title":"Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: inhibitory effect of glycosaminoglycan sulodexide","volume":"1864","author":"D Ligi","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.21037\/cdt.2016.11.22","article-title":"Incidence and interventions for post-thrombotic syndrome","volume":"6","author":"J J Farrell","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/000331970405500302","article-title":"Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry","volume":"55","author":"B M Errichi","year":"2004","journal-title":"Angiology"},{"issue":"03","key":"ref53","first-page":"238","article-title":"Prevention of recurrent venous thrombosis and post-thrombotic syndrome","volume":"66","author":"G Belcaro","year":"2018","journal-title":"Minerva Cardioangiol"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/1076029614533143","article-title":"The efficacy of sulodexide in the prevention of postthrombotic syndrome","volume":"20","author":"R Luzzi","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"issue":"20","key":"ref55","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.115.016930","article-title":"Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"132","author":"G M Andreozzi","year":"2015","journal-title":"Circulation"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1055\/s-0040-1716874","article-title":"Sulodexide versus control and the risk of thrombotic and hemorrhagic events: meta-analysis of randomized trials","volume":"46","author":"B Bikdeli","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1185\/03007999209115223","article-title":"Sulodexide and the microcirculatory component in microphlebopathies","volume":"13","author":"M Cospite","year":"1992","journal-title":"Curr Med Res Opin"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1185\/03007999309111538","article-title":"Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency","volume":"13","author":"M Saviano","year":"1993","journal-title":"Curr Med Res Opin"},{"issue":"09","key":"ref59","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12325-016-0359-9","article-title":"Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life","volume":"33","author":"N Elleuch","year":"2016","journal-title":"Adv Ther"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s12325-020-01270-9","article-title":"Sulodexide in the treatment of chronic venous insufficiency: results of the all-Russian multicenter ACVEDUCT program","volume":"37","author":"A V Chupin","year":"2020","journal-title":"Adv Ther"},{"issue":"06","key":"ref61","doi-asserted-by":"crossref","first-page":"558","DOI":"10.23736\/S0392-9590.17.03805-6","article-title":"Chronic venous disease treated with sulodexide: a survey among primary care physicians in Mexico","volume":"36","author":"L F Flota Cervera","year":"2017","journal-title":"Int Angiol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2006.12.009","article-title":"Sulodexide induces hepatocyte growth factor release in humans","volume":"558","author":"J Borawski","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0037-1613116","article-title":"Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers","volume":"87","author":"S Coccheri","year":"2002","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref64","first-page":"CD010694","article-title":"Sulodexide for treating venous leg ulcers","volume":"2016","author":"B Wu","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.23736\/S0392-9590.16.03718-4","article-title":"Sulodexide and phlebotonics in the treatment of venous ulcer","volume":"36","author":"A Gonz\u00e1lez Ochoa","year":"2017","journal-title":"Int Angiol"},{"issue":"09","key":"ref66","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/02683555211015020","article-title":"Systematic literature review and network Meta-analysis of sulodexide and other drugs in chronic venous disease","volume":"36","author":"G Pompilio","year":"2021","journal-title":"Phlebology"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"2048004020907002","DOI":"10.1177\/2048004020907002","article-title":"Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: a systematic review and meta-analysis","volume":"9","author":"A V Gaddi","year":"2020","journal-title":"JRSM Cardiovasc Dis"},{"issue":"10","key":"ref68","first-page":"351","article-title":"Hemorheology and tissue oxygenation in hypertensives with lipoidoproteinosis and peripheral occlusive arterial disease (POAD) treated with sulodexide and pravastatine and evaluated with laser assisted optical rotational red cell analyzer (LORCA) and transcutaneous oxymetry","volume":"47","author":"G Cicco","year":"1999","journal-title":"Minerva Cardioangiol"},{"key":"ref69","first-page":"6275","article-title":"Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review","volume":"9","author":"R Li","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"06","key":"ref70","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfp724","article-title":"Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy","volume":"25","author":"M Rossini","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"02","key":"ref71","first-page":"161","article-title":"Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies","volume":"53","author":"D S Zili\u015fteanu","year":"2015","journal-title":"Rom J Intern Med"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2984680","DOI":"10.1155\/2020\/2984680","article-title":"Renal effects of sulodexide in type 2 diabetic patients without nephrotic range proteinuria","volume":"2020","author":"K Yongwatana","year":"2020","journal-title":"J Diabetes Res"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1056-8727(00)00134-3","article-title":"The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderly patients","volume":"15","author":"T Koblik","year":"2001","journal-title":"J Diabetes Complications"},{"issue":"03","key":"ref74","first-page":"99","article-title":"Significance of endothelial protection in treatment of patients with class c6 chronic venous disease and type 2 diabetes mellitus [in Russian]","volume":"21","author":"S E Katorkin","year":"2015","journal-title":"Angiol Sosud Khir"},{"issue":"06","key":"ref75","first-page":"917","article-title":"The treatment of elderly and senile patients with venous trophic ulcers and type 2 diabetes mellitus [in Russian]","volume":"30","author":"N O Zakharova","year":"2017","journal-title":"Usp Gerontol"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00417-014-2746-8","article-title":"Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS)","volume":"253","author":"J H Song","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"109885","DOI":"10.1016\/j.exer.2024.109885","article-title":"Retinal microcirculation: a window into systemic circulation and metabolic disease","volume":"242","author":"Y Yuan","year":"2024","journal-title":"Exp Eye Res"},{"issue":"11","key":"ref78","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Z L Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"02","key":"ref79","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"12","key":"ref80","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","article-title":"Diabetic macular edema: evidence-based management","volume":"66","author":"D J Browning","year":"2018","journal-title":"Indian J Ophthalmol"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7861\/clinmed.2021-0792","article-title":"Diabetic retinopathy for the non-ophthalmologist","volume":"22","author":"T H Fung","year":"2022","journal-title":"Clin Med (Lond)"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0161-6420(13)38009-9","article-title":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7","volume":"98","author":"E TDRSR Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"05","key":"ref83","first-page":"75","article-title":"Diabetic retinopathy: early diagnosis and effective treatment","volume":"107","author":"A N Kollias","year":"2010","journal-title":"Dtsch Arztebl Int"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1077669","DOI":"10.3389\/fendo.2022.1077669","article-title":"Diabetic retinopathy: looking forward to 2030","volume":"13","author":"T E Tan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"ref85","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","article-title":"Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy","volume":"2","author":"C C Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/antiox12020388","article-title":"Sulodexide prevents hyperglycemia-induced endothelial dysfunction and oxidative stress in porcine retinal arterioles","volume":"12","author":"A Dauth","year":"2023","journal-title":"Antioxidants"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"11532","DOI":"10.1038\/s41598-021-90987-w","article-title":"Sulodexide reduces glucose induced senescence in human retinal endothelial cells","volume":"11","author":"A Gericke","year":"2021","journal-title":"Sci Rep"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bcp.2017.06.130","article-title":"Sulodexide prevents activation of the PLA2\/COX-2\/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE\/RAGE","volume":"142","author":"G Giurdanella","year":"2017","journal-title":"Biochem Pharmacol"},{"issue":"06","key":"ref89","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.ASN.0000014254.87188.E5","article-title":"Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial","volume":"13","author":"G Gambaro","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"ref90","first-page":"81","article-title":"The effects of sulodexide on diabetic retinopathy","volume":"48","author":"F Rubbi","year":"2000","journal-title":"Minerva Cardioangiol"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"010427","DOI":"10.7189\/jogh.09.010427","article-title":"Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors","volume":"9","author":"P Song","year":"2019","journal-title":"J Glob Health"},{"issue":"05","key":"ref92","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","article-title":"Retinal vein occlusion (RVO) guideline: executive summary","volume":"36","author":"L Nicholson","year":"2022","journal-title":"Eye (Lond)"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0161-6420(93)31633-7","article-title":"Arteriovenous crossing patterns in branch retinal vein occlusion","volume":"100","author":"J Zhao","year":"1993","journal-title":"Ophthalmology"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"U Schmidt-Erfurth","year":"2019","journal-title":"Ophthalmologica"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41433-021-01553-7","article-title":"The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy","volume":"36","author":"L Nicholson","year":"2022","journal-title":"Eye (Lond)"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.thromres.2009.05.007","article-title":"Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study","volume":"125","author":"W Ageno","year":"2010","journal-title":"Thromb Res"},{"issue":"09","key":"ref97","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3324\/haematol.2010.023614","article-title":"Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials","volume":"95","author":"A Lazo-Langner","year":"2010","journal-title":"Haematologica"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtha.2022.10.003","article-title":"Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis","volume":"21","author":"E Valeriani","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/24741264211028508","article-title":"Central retinal vein occlusion: the effect of antiplatelet and anticoagulant agents","volume":"6","author":"G N Thomas","year":"2021","journal-title":"J Vitreoretin Dis"},{"issue":"04","key":"ref101","first-page":"341","article-title":"Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET)","volume":"20","author":"F Paciullo","year":"2022","journal-title":"Blood Transfus"},{"issue":"11","key":"ref102","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1167\/iovs.18-23994","article-title":"Pathophysiological role of VEGF on retinal edema and nonperfused areas in mouse eyes with retinal vein occlusion","volume":"59","author":"A Nishinaka","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"ref103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.5483\/BMBRep.2014.47.11.009","article-title":"Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy","volume":"47","author":"H Jo","year":"2014","journal-title":"BMB Rep"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"109","DOI":"10.23736\/S0026-4725.19.04891-6","article-title":"Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol\u00ae, ticlopidine, or sulodexide","volume":"67","author":"G Belcaro","year":"2019","journal-title":"Minerva Cardioangiol"},{"issue":"07","key":"ref105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"K G Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"issue":"04","key":"ref106","doi-asserted-by":"crossref","first-page":"e14746","DOI":"10.1111\/dme.14746","article-title":"Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study","volume":"39","author":"T Peto","year":"2022","journal-title":"Diabet Med"},{"issue":"19","key":"ref107","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.3390\/ijerph191912603","article-title":"Transition from laser to intravitreal injections for diabetic retinopathy: hospital utilization and costs from an extended healthcare perspective","volume":"19","author":"S NW Hertzberg","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"02","key":"ref108","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ndt\/gfr370","article-title":"Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion","volume":"27","author":"A Pletinck","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"02","key":"ref109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/fcp.12418","article-title":"Sulodexide inhibits angiogenesis via decreasing Dll4 and Notch1 expression in mouse proepicardial explant cultures","volume":"33","author":"J Niderla-Bieli\u0144ska","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"issue":"05","key":"ref110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/jpm14050501","article-title":"Non-invasive retinal vessel analysis as a predictor for cardiovascular disease","volume":"14","author":"R E Iorga","year":"2024","journal-title":"J Pers Med"},{"issue":"05","key":"ref111","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2337\/dc12-1311","article-title":"Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial","volume":"36","author":"H C Gerstein","year":"2013","journal-title":"Diabetes Care"},{"issue":"52","key":"ref112","doi-asserted-by":"crossref","first-page":"e28424","DOI":"10.1097\/MD.0000000000028424","article-title":"Impact of retinal vein occlusion on cardiovascular events in elderly Japanese patients","volume":"100","author":"R Umeya","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"09","key":"ref113","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/IAE.0000000000002472","article-title":"ASSOCIATION OF RETINAL VEIN OCCLUSION WITH CARDIOVASCULAR EVENTS AND MORTALITY: A Systematic Review and Meta-analysis","volume":"39","author":"C Y Wu","year":"2019","journal-title":"Retina"},{"issue":"07","key":"ref114","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1097\/HJH.0000000000002057","article-title":"Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: results from the Gutenberg Retinal Vein Occlusion Study","volume":"37","author":"K A Ponto","year":"2019","journal-title":"J Hypertens"},{"issue":"06","key":"ref115","first-page":"589","article-title":"Sulodexide suppresses inflammation in patients with chronic venous insufficiency","volume":"34","author":"T Urbanek","year":"2015","journal-title":"Int Angiol"},{"issue":"01","key":"ref116","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5114\/ada.2022.122605","article-title":"Concentrations of selected acute phase proteins in patients with chronic venous insufficiency treated with Sulodexide. Part 1","volume":"40","author":"B Kaczmarek","year":"2023","journal-title":"Postepy Dermatol Alergol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"172038","DOI":"10.1155\/2015\/172038","article-title":"Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial","volume":"2015","author":"B Satirapoj","year":"2015","journal-title":"J Diabetes Res"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T23:46:08Z","timestamp":1743551168000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":116,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2025,4,1]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791232","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}